Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

The United States would start imposing tariffs and other measures on Russia if Moscow showed no progress toward ending ...

President Donald Trump said his administration would “deploy every tool” to get drug prices reduced from large pharmaceutical ...

President Trump pressures pharmaceutical companies to lower drug prices, threatening action if they don't comply within 60 ...

Pfizer Inc. (NYSE: PFE), a global pharmaceutical giant with a market capitalization of $138.21 billion, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Pfizer’s pipeline remains a crucial component of its long-term growth strategy. The company has made significant strides in key therapeutic areas, particularly in oncology and obesity treatments.

Pfizer Inc. s fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research spending and legal costs also hurt the bottom line.